Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis

BACKGROUND: The phase 3 JAVELIN Bladder 100 trial showed significantly prolonged overall survival (OS) with avelumab as first-line (1L) maintenance therapy + best supportive care (BSC) vs BSC alone in patients with advanced urothelial carcinoma (UC) that had not progressed with 1L platinum-containin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Yamamoto, Yoshiaki, Tsuchiya, Norihiko, Kanayama, Hiroomi, Eto, Masatoshi, Miyake, Hideaki, Powles, Thomas, Yoshida, Mizuki, Koide, Yuichiro, Umeyama, Yoshiko, di Pietro, Alessandra, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816770/
https://www.ncbi.nlm.nih.gov/pubmed/34973108
http://dx.doi.org/10.1007/s10147-021-02067-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8816770/
https://www.ncbi.nlm.nih.gov/pubmed/34973108
http://dx.doi.org/10.1007/s10147-021-02067-8

Ejemplares similares